Clinical Trial Update: Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing cladribine in combination with GAP for refractory/relapsed acute lymphoblastic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Cladribine (cladribine)
• GAP (GAP)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: UNKNOWN